share_log

Earnings Call Summary | Nutex Health(NUTX.US) Q1 2024 Earnings Conference

Earnings Call Summary | Nutex Health(NUTX.US) Q1 2024 Earnings Conference

業績電話會議摘要 | Nutex Health (NUTX.US) 2024 年第一季度業績會議
富途資訊 ·  05/11 08:13  · 電話會議

The following is a summary of the Nutex Health (NUTX) Q1 2024 Earnings Call Transcript:

以下是Nutex Health(NUTX)2024年第一季度業績電話會議記錄的摘要:

Financial Performance:

財務業績:

  • Nutex Health's total revenue increased by 20% to $67.5 million for Q1 2024. Gross profit for the same period saw a growth of 113%.

  • Revenue for mature hospitals saw a growth of 6.7% for Q1 2024 against the same period last year.

  • The population health division's revenue grew by 5.4%.

  • The net loss was reduced drastically in Q1 2024 to -$364,000 from -$5.1 million in Q1 2023.

  • Cash and cash equivalents increased to $30 million by March 31, 2024.

  • 2024年第一季度,Nutex Health的總收入增長了20%,達到6,750萬美元。同期毛利增長了113%。

  • 2024年第一季度成熟醫院的收入與去年同期相比增長了6.7%。

  • 人口健康部門的收入增長了5.4%。

  • 淨虧損從2023年第一季度的-510萬美元大幅減少至2024年第一季度的-36.4萬美元。

  • 到2024年3月31日,現金和現金等價物增加到3000萬美元。

Business Progress:

業務進展:

  • Nutex Health opened four new hospitals in 2023, contributing to the system-wide increase in ER volumes by 21%.

  • There was a significant increase of 78% in the number of Medicare Advantage lives quarter-over-quarter.

  • The company is planning to open four more hospitals in 2024 subject to certain financial metrics and continues to push cost-cutting measures.

  • Revenue per patient, collections, and managing the impact of the No Surprises Act remain areas of focus.

  • The population health division continues to experience profitability and growth in Medicare Advantage lives, and has introduced new Independent Practice Associations (IPAs) in various regions.

  • Nutex Health 在 2023 年開設了四家新醫院,使全系統急診量增長了 21%。

  • Medicare Advantage的壽命同比大幅增長了78%。

  • 該公司計劃在2024年再開設四家醫院,但須遵守某些財務指標,並將繼續推動削減成本的措施。

  • 每位患者的收入、收款和管理《無意外法》的影響仍然是重點領域。

  • 人口健康部門在Medicare Advantage壽命方面繼續實現盈利和增長,並在各個地區推出了新的獨立執業協會(IPA)。

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論